Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Next Previous
X
Search
Trial Profile

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hypochlorous acid (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Realm Therapeutics

    • Most Recent Events

    • 22 Sep 2018 Status changed from active, no longer recruiting to discontinued.
    • 17 Sep 2018 According to a Realm Therapeutics media release, the overall results of this trial did not meet the threshold for continued investment and the company decided to discontinue all of the drug development programs, which are based on the Company's proprietary technology.
    • 14 Aug 2018 According to Realm Therapeutics media release, company announced preliminary top-line data from this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top